High Grade Glioma — The Arrival of the Molecular Diagnostic Era for Patients over the Age of 65 Years in the UK
- 23 April 2013
- journal article
- editorial
- Published by Elsevier in Clinical Oncology
- Vol. 25 (7) , 391-393
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-statusActa Neuropathologica, 2012
- MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCRJournal of Translational Medicine, 2012
- Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 casesNeuro-Oncology, 2011
- Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBMPLOS ONE, 2011
- Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomideJournal of Neuro-Oncology, 2010
- MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMANeurology, 2009
- Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomasNeuro-Oncology, 2009
- Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastomaCancer, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005